school
Macau Periodical Index (澳門期刊論文索引)
- Author
- Leong,；Nga；Cheng
- Title
- Long-term remission by secukinumab in erythrodermic psoriasis with metabolic syndrome: report of two cases
- Journal Name
- 鏡湖醫學
- Pub. Info
- 2023年12月, 總第49期, 第23卷第2期, pp. 56-57
- Link
- https://mjokw.magtechjournal.com/CN/Y2023/V23/I2
- Keyword
- Erythrodermic psoriasis, EP；Metabolic syndrome
- Abstract
- Psoriasis is a chronic inflammatory systemic disorder which is strongly associated with metabolic syndrome. Erythrodermic psoriasis (EP) is a severe type of psoriasis that causes severe physical and mental impairment. Evidence-based data on EP treatment are limited in recent years. Although conventional systemic treatments such as acitretin, cyclosporine, methotrexate and steroids show efficacy in patients with EP, these treatments have many limitations and intolerance. Improvement of this syndrome can seriously affect patients’ quality of life (DLQI). Secukinumab is an interleukin-17A inhibitor human monoclonal antibody which has been approved for the treatment of moderate to severe plaque psoriasis[2]. There has been no research on the use of secukinumab in EP patients with metabolic syndrome. We present two EP patients with metabolic syndrome who achieved and maintained successful treatment and remission for more than 52 weeks with secukinumab. Paragraph Headings: 1. Introduction 2. Case reports 2.1. Patient 1 2.2. Patient 2 3. Discussion 4. Conclusion Figures: 1. Case 1 at baseline (1A) and after 52 weeks of treatment with secukinumab 300 mg (1B) 2. Case 2 at baseline (2A and 2B) and after 52 weeks of treatment with secukinumab 300 mg (2C and 2D） 3. PASI trends in erythrodermic psoriasis patients with metabolic syndrome treated with secukinumab from baseline to week 52